GSK Announces Intention To Sell ~385M Shares In Haleon
$GSK
$HLN
Biotechnology: Pharmaceutical Preparations
Health Care
Package Goods/Cosmetics
Consumer Discretionary
GSK Announces Intention To Sell ~385M Shares In Haleon
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 1/27/2026 | Neutral | Citigroup | ||
| 1/23/2026 | Equal Weight → Overweight | Barclays | ||
| 1/6/2026 | Equal Weight → Underweight | Barclays | ||
| 11/25/2025 | Underperform → Neutral | BofA Securities | ||
| 9/16/2025 | Overweight → Equal Weight | Barclays | ||
| 9/10/2025 | Neutral → Buy | Goldman | ||
| 6/3/2025 | Buy → Hold | Berenberg | ||
| 5/27/2025 | $13.40 | Neutral → Outperform | BNP Paribas Exane |
Citigroup initiated coverage of GlaxoSmithKline with a rating of Neutral
Barclays upgraded Haleon plc from Equal Weight to Overweight
Barclays downgraded GlaxoSmithKline from Equal Weight to Underweight
Bora manufactures more than 20 commercial products for GSK at its Mississauga facility, supporting infectious disease, mental health, dermatology, & other critical therapeutic areas Bora Pharmaceuticals Co., Ltd. (("Bora", TWSE: 6472, OTCQX:BORAY), a global leader in pharmaceutical manufacturing, and GSK (LSE/NYSE:GSK) have signed a strategic agreement to renew a five-year manufacturing partnership. Bora purchased the Mississauga facility from GSK in 2020. This renewed collaboration reinforces the long-standing relationship between the two companies and expands the partnership, allowing GSK access to multiple sites within the Bora network, including its newest oral solid dose (OSD) site i
Reduction observed in RSV-related hospitalizations in adults aged ≥60 years1 An observed reduction in major adverse cardiovascular events* in adults aged ≥60 yearsǂ2 during RSV-related hospitalization Risk reduction observed against severe flare-ups of chronic obstructive pulmonary disease (COPD) and asthma†2 during RSV-related hospitalization GSK plc (LSE/NYSE:GSK) today announced new effectiveness data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) at RSVVW'26, the 9th Conference of the Respiratory Syncytial Virus Foundation (ReSViNET) in Rome, Italy. GSK is presenting 19 abstracts at the congress and supporting a further 3, reflecting GSK's leadership in research
The breakthrough formula starts to repair sensitive areas of teeth after 60 seconds for substantial sensitivity relief in 3 days, delivering long-lasting relief with twice-daily brushing Key Takeaways Sensodyne unveils Clinical Repair, the brand's newest toothpaste option for sensitive teeth. Clinical Repair: Starts to repair sensitive areas of teeth after 60 seconds* for clinically proven long-lasting relief**. With twice daily brushing, Clinical Repair generates a protective layer that restrengthens with every use – protecting against sensitivity returning** Designed to target and strengthen enamel, addressing sensitivity at the source. Developed with a science-backe
6-K - GSK plc (0001131399) (Filer)
IRANNOTICE - GSK plc (0001131399) (Filer)
20-F - GSK plc (0001131399) (Filer)
4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)
3 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)
4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)
LONDON, June 24, 2025 /PRNewswire/ -- Haleon (LSE: HLN) (NYSE:HLN) today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025. This appointment follows Franck Riot deciding to leave Haleon after six years in the business. Carl joins Haleon from the Estée Lauder Companies Inc. where he has spent 13 years as Executive Vice President, Global Innovation and Research and Development. Carl previously spent over 20 years at P&G across Home, Health and Beauty Care. Brian McNamara, Haleon's Chief Executive Officer commented: "I am delighted to welcome Carl to Haleon. Carl is a world-renowned leader in R&D, with significant experi
Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.
Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov
Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replacedLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA
BOSTON, June 3, 2024 /PRNewswire/ -- Yellow Wood Partners LLC ("Yellow Wood"), a Boston-based private equity firm known for investing in consumer brands and companies, is pleased to announce that its portfolio company, Suave Brands Company, has successfully completed the acquisition of the ChapStick brand from Haleon (NYSE:HLN). This transaction also results in Haleon becoming a shareholder in Suave Brands Company. Suave Brands Company Chief Executive Officer, Daniel Alter, said, "As we continue to build Suave Brands Company as the top independent North American beauty & personal care company by combining the agility of a start-up with the power of market leading brands, the addition of Cha
SC 13G - Haleon plc (0001900304) (Subject)
SC 13G/A - GSK plc (0001131399) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)